Fidelity Disruptive Medicine ETF (FMED)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Innovative ETF Strategies That Are Paying Off This Summer
Exchange-traded fund (ETF) inflows reached an astonishing $1 trillion for the first half of 2026 alone, the latest sign that investors everywhere are continuing to lean heavily on these vehicles to simplify their experience and add built-in diversification to their portfolios. Unsurprisingly, the number of funds available continues to skyrocket, although many investors stick with major ETFs tracking the S&P or other prominent indexes instead of venturing into unique strategies.
Disruptive Healthcare Stocks ETF FMED Hits Milestone in June
While healthcare stocks may not always seem the most enticing, they've quietly surged over the last month. The active healthcare tech ETF, FMED, which focuses on industry disruptors, saw its June performance significantly leapfrog its overall YTD numbers.
2 ETFs That Capitalize on the “Silver Tsunami”
An aging population is leading to a profound demographic shift known as the “Silver Tsunami.” With more Baby Boomers reaching retirement age, the demand for senior living facilities and medicinal innovation is increasing.
AI Opens The Door to This Active Healthcare ETF
Like many sectors, the healthcare industry is poised for disruption from artificial intelligence (AI) technology, which may create an investment opportunity for the Fidelity Disruptive Medicine ETF (FMED). Marred by regulatory scrutiny and rising costs, the healthcare sector overall has had its fair share of challenges in 2025.
First Look At FMED: Poor Performance Merits A Strong Sell Rating
Fidelity Disruptive Medicine ETF invests in innovative healthcare companies, focusing on sectors like robotic surgery, genomics, and advanced diagnostics, aiming to disrupt traditional medical practices. The ETF employs a bottom-up stock picking approach, benchmarking against the MSCI ACWI Index and MSCI All Country World Healthcare Equal Weighted Index. Based on the results so far, this strategy has been a dud, earning this ETF another Strong Sell rating for this series of ETFs.
As Biotech Outlook Grows Healthier, Look to Disruptive ETF FMED
Could now be the time to invest in biotech? The space, which performed well in 2020 and 2021, dropped off in the interim amid high interest rates and slowing deal-making.
